Treating osteoporosis: Economic aspects of bisphosphonate therapy

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 11, 2006, Pages 1457-1467

  Kennedy, Courtney C ^a   Papaioannou, Alexandra ^a   Adachi, Jonathan D ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Bisphosphonate; Bone mineral density; Cost effectiveness analysis; Cost utility analysis; Economic evaluation; Fractures; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ABDOMINAL PAIN; AGE DISTRIBUTION; BONE DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HIGH RISK POPULATION; HUMAN; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW;

COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG TOLERANCE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS; QUALITY OF LIFE;

EID: 33746840920     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.11.1457     Document Type: Review

References (95)

1. OSNES EK, LOFTHUS CM, MEYER HE et al.: Consequences of hip fracture on activities of daily life and residential needs. Osteoporos. Int. (2004) 15:567-574.
2. JOHNELL O, KANIS JA, ODEN A et al.: Mortality after osteoporotic fractures. Osteoporos. Ins. (2004) 15:38-42.
3. PAPAIOANNOU A, WIKTOROWICZ ME, ADACHI JD et al.: Mortality, independence in living, and re-fracture, one year following hip fracture in Canadians. J. Obstet. Gynaecol. Can. (2000) 22:591-597.
4. OLEKSIK AM, EWING S, SHEN W et al.: Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos. Ins. (2005) 16:861-870.
5. HALLBERG I, ROSENQVIST AM, KARTOUS L et al.: Health-related quality of life after osteoporotic fractures. Osteoporos. Int. (2004) 15:834-841.
6. JOHNELL O KANIS J: Epidemiology of osteoporotic fractures. Osteoporos. Int. (2005) 16(Suppl. 2):S3-S7.
7. JACKSON SA, TENENHOUSE A, ROBERTSON L: Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos. Int. (2000) 11:680-687.
8. RIGGS BL MELTON LJ III: The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone (1995) 17:505S-511S.
9. MELTON LJ, III, GABRIEL SE, CROWSON CS et al.: Cost-equivalence of different osteoporotic fractures. Osteoporos. Int. (2003) 14:383-388.
10. JOHNELL O KANIS JA: An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos. Int. (2004) 15:897-902.
11. KANIS JA, ODEN A, JOHNELL O et al.: The components of excess mortality after hip fracture. Bone (2003) 32:468-473.
12. FARAHMAND BY, MICHAELSSON K, AHLBOM et al.: Survival after hip fracture. Osteoporos. Int. (2005) 16(12):1583-1590.
13. NIH CONSENSUS DEVELOPMENT PANEL ON OSTEOPOROSIS PREVENTION, DIAGNOSIS, AND THERAPY: Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 285:785-795.
14. GOEREE R, O'BRIEN B, PETTITT D et al.: An assessment of the burden of illness due to osteoporosis in Canada. J. Soc. Obstet. Gynaecol. (1996) 18:15-24.
15. WIKTOROWICZ ME, GOEREE R, PAPAIOANNOU A et al.: Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos. Int. (2001) 12:271-278.
16. STEVENSON M, LLOYD JM, DE NIGRIS E et al.: A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol. Assess (2005) 9:1-160.
17. KEEN RW: Burden of osteoporosis and fractures. Curr. Osteoporos. Rep (2003) 1:66-70.
18. REGINSTER JY: Treatment of postmenopausal osteoporosis. Br. Med. J. (2005) 330:859-860.
19. LAUPACIS A: Osteoporosis guidelines. CMAJ (2003) 168:1644-1645.
20. Prevention and management of osteoporosis. World Health Organ. Tech. Rep. Ser (2003) 921:1-164.
21. CRANNEY A, WELLS G, WILLAN A et al.: Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. (2002) 23:508-516.
22. CRANNEY A, TUGWELL P, ADACHI J et al.: Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev (2002) 23:517-523.
23. ADACHI JD, RIZZOLI R, BOONEN S et al.: Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin. Exp. Res (2005) 17:150-156.
24. HARRINGTON JT, STE-MARIE LG, BRANDI ML et al.: Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif. Tissue Int. (2004) 74:129-135.
25. BAGGER YZ, TANKO LB, ALEXANDERSEN P et al.: The long-term predictive value of bone mineral density measurements for fracture risk is independent of the site of measurement and the age at diagnosis: results from the Prospective Epidemiological Risk Factors study. Osteoporos. Int. (2006) 17(3):471-477.
26. EASTELL R, BARTON I, HANNON RA et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res (2003) 18:1051-1056.
27. WATTS NB, GEUSENS P, BARTON IP et al.: Relationship between changes in bmd and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J. Bone Miner. Res. (2005) 20:2097-2104.
28. KANIS JA, JOHNELL O, DE LAET C et al.: A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 35:375-382.
29. RESZKA AA RODAN GA: Bisphosphonate mechanism of action. Curr. Rheumatol. Rep (2003) 5:65-74.
30. RUSSELL RG ROGERS MJ: Bisphosphonates: from the laboratory to the clinic and back again. Bone (1999) 25:97-106.
31. CRANNEY A, GUYATT G, KROLICKI N et al.: A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos. Ins. (2001) 12:140-151.
32. BLACK DM, CUMMINGS SR, KARPF DB et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 348:1535-1541.
33. QUANDT SA, THOMPSON DE, SCHNEIDER DL et al.: Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin. Proc (2005) 80:343-349.
34. ROUX C, SEEMAN E, EASTELL R et al.: Efficacy of risedronate on clinical vertebral fractures within six months. Curr. Med. Res. Opin (2004) 20:433-439.
35. MCCLUNG MR, GEUSENS P, MILLER PD et al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med (2001) 344:333-340.
36. FELSENBERG D, MILLER P, ARMBRECHT G et al.: Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone (2005) 37:651-654.
37. BLACK DM, BILEZIKIAN JP, ENSRUD KE et al.: One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N. Engl. J. Med. (2005) 353:555-565.
38. EISMAN JA, RIZZOLI R, ROMAN-IVORRA J et al.: Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr. Med Res. Opin (2004) 20:699-705.
39. HARRIS ST, WATTS NB, LI Z et al.: Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr. Med Res. Opin (2004) 20:757-764.
40. BISWAS PN, WILTON LV, SHAKIR SA: Pharmacovigilance study of alendronate in England. Osteoporos. Int. (2003) 14:507-514.
41. BROWN JP JOSSE RG: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. (2002) 167:S1-S34.
42. HODGSON SF, WATTS NB, BILEZIKIAN JP et al.: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr. Pract (2003) 9:544-564.
43. ROYAL COLLEGE OF PHYSICIANS: Osteoporosis: Clinical Guidelines for Prevention and Treatment. Royal College of Physicians (1999).
44. BOONEN S, BODY JJ, BOUTSEN Y et al.: Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int. (2005) 16:239-254.
45. KANIS JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet (2002) 359:1929-1936.
46. SIMINOSKI K, LESLIE WD, FRAME H et al.: Recommendations for bone mineral density reporting in Canada. Can. Assoc. Radiol. J. (2005) 56:178-188.
47. KANIS JA, BORGSTROM F, DE LAET C et al.: Assessment of fracture risk. Osteoporos. Int. (2005) 16:581-589.
48. KANIS JA, JOHNELL O, ODEN A, DAWSON A, DE LAET C, JONSSON B: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. (2001) 12(12):989-995.
49. CRANNEY A, WALDEGGER L, GRAHAM ID et al.: Systematic assessment of the quality of osteoporosis guidelines. BMC. Musculoskelet. Disord (2002) 3:20.
50. LEWIECKI EM, WATTS NB, MCCLUNG MR et al.: Official positions of the international society for clinical densitometry J. Clin. Endocrinol. Metab. (2004) 89:3651-3655.
51. US PREVENTIVE SERVICES TASK FORCE: Screening for Osteoporosis in Postmenopausal Women: Recommendations and Rationale (2002).
52. KHAN AA, BROWN JP, KENDLER D et al.: The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ (2002) 167:1141-1145.
53. NATIONAL OSTEOPOROSIS FOUNDATION: Physician's guide to prevention and treatment of osteoporosis (2003).
54. SHIELL A, DONALDSON C, MITTON C et al.: Health economic evaluation. J. Epidemiol. Community Health (2002) 56:85-88.
55. JOHANNESSON M: Theory and methods of economic evaluation of health care. Kluwer Academic Publishers, Dordrecht, the Netherlands (1996).
56. ALSARRAF AA FOWLER R: Health, economic evaluation, and critical care. J. Crit. Care (2005) 20:194-197.
57. LAUPACIS A, FEENY D, DETSKY AS et al.: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ (1992) 146:473-481.
58. WEINSTEIN MC STASON WB: Foundations of cost-effectiveness analysis for health and medical practices. N. Engl. J. Med. (1977) 296:716-721.
59. SINGER ME APPLEGATE KE: Cost-effectiveness analysis in radiology. Radiology (2001) 219:611-620.
60. NEUMANN P: Using cost-effectiveness analysis to impove health care: opportunities and barriers. Oxford University Press, New York (2005).
61. GOLD MR, SIEGEL J, RUSSELL LB, WEINSTEIN MC (Eds): Cost-effectiveness in health and medicine, 1st edn. Oxford University Press, New York (1996).
62. TOSTESON AN: Quality of life in the economic evaluation of osteoporosis prevention and treatment. Spine (1997) 22:58S-62S.
63. PRIETO L SACRISTAN JA: Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual. Life Outcomes (2003) 1:80.
64. TOSTESON AN, GABRIEL SE, GROVE MR et al.: Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos. Int. (2001) 12:1042-1049.
65. TOSTESON AN HAMMOND CS: Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics (2002) 20:289-303.
66. KANIS JA JONSSON B: Economic evaluation of interventions for osteoporosis. Osteoporos. Int. (2002) 13:765-767.
67. KANIS JA, BRAZIER JE, STEVENSON M et al.: Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol. Assess. (2002) 6:1-146.
68. RAFTERY J: NICE: faster access to modern treatments? Analysis of guidance on health technologies. Br. Med. J. (2001) 323:1300-1303.
69. UBEL PA, HIRTH RA, CHERNEW ME et al.: What is the price of life and why doesn't it increase at the rate of inflation? Arch. Intern. Med. (2003) 163:1637-1641.
70. JOHNELL O, JONSSON B, JONSSON L et al.: Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics (2003) 21:305-314.
71. BORGSTROM F, CARLSSON A, SINTONEN H et al.: The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos. Int. (2006) 17:996-1007.
72. KANIS JA, JOHNELL O, ODEN A et al.: Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos. Int. (2005) 16:6-14.
73. SCHOUSBOE JT, ENSRUD KE, NYMAN JA et al.: Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J. Am. Geriatr. Soc (2005) 53:1697-1704.
74. IGLESIAS CP, TORGERSON DJ, BEARNE A et al.: The cost utility of bisphosphonate treatment in established osteoporosis. QJM (2002) 95:305-311.
75. BRECHT JG, KRUSE HP, FELSENBERG D et al.: Pharmacoeconomic analysis of osteoporosis treatment with risedronate. Int. J. Clin. Pharmacol. Res (2003) 23:93-105.
76. BRECHT JG, KRUSE HP, MOHRKE W et al.: Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int. J. Clin. Pharmacol. Res (2004) 24:1-10.
77. CHRISTENSEN PM, BRIXEN K, GYRD-HANSEN D et al.: Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin. Pharmacol. Toxicol. (2005) 96:387-396.
78. BORGSTROM F, JOHNELL O, JONSSON B et al.: Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone (2004) 34:1064-1071.
79. SORNAY-RENDU E, MUNOZ F, GARNERO P et al.: Identification of Osteopenic Women at High Risk of Fracture: The OFELY Study. J. Bone Miner. Res. (2005) 20:1813-1819.
80. BLACK DM, STEINBUCH M, PALERMO L et al.: An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos. Int. (2001) 12:519-528.
81. SCHOUSBOE JT, NYMAN JA, KANE RL et al.: Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann. Intern. Med. (2005) 142:734-741.
82. SCHOUSBOE JT, ENSRUD KE, NYMAN JA et al.: Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos. Int. (2005) 16:1883-1893.
83. MULLINS CD OHSFELDT RL: Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J. Manag. Care Pharm. (2003) 9:150-158.
84. KANIS JA, DAWSON A, ODEN A et al.: Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos. Int. (2001) 12:356-361.
85. CRANNEY A ADACHI JD: Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. (2005) 28:721-730.
86. GRIMA D, BURGE R, BECKER DL et al.: Short-term cost-effectiveness of bisphosphonate therapies for postmenopausal osteoporotic women at high risk of fracture. P&T (2002) 27:448-455.
87. MELTON LJ, III, JOHNELL O, LAU E et al.: Osteoporosis and the global competition for health care resources. J. Bone Miner. Res. (2004) 19:1055-1058.
88. LAUPACIS A: Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? CMAJ (2002) 166:44-47.
89. CUMMINGS SR: Foreward. Osteoporos. Int. (1998):S1-S2.
90. CRANNEY A, COYLE D, WELCH V et al.: A review of economic evaluation in osteoporosis. Arthritis Care Res. (1999) 12:425-434.
91. ZETHRAEUS N, BEN SEDRINE W, CAULIN F et al.: Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos. Int. (2002) 13:841-857.
92. FRAENKEL L, CONSTANTINESCU F, OBERTO-MEDINA M et al.: Women's preferences for prevention of bone loss. J. Rheumatol. (2005) 32:1086-1092.
93. KANIS JA, BORGSTROM F, JOHNELL O et al.: Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos. Int. (2004) 15:862-871.
94. CUMMINGS SR, BLACK DM, THOMPSON DE et al.: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1998) 280:2077-2082.
95. REGINSTER JY, ABADIE E, DELMAS P et al.: Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos. Int. (2006) 17(1):1-7.